JPRN-UMIN000047758
Completed
N/A
Multicenter study for biomarker on therapeutic effect and safety of Atezolizumab + Bevacizumab in patients with unresectable hepatocellular carcinoma - Study on biomarkers in treatment with Atezolizumab + Bevacizumab for hepatocellular carcinoma
agoya University Graduate School of Medicine0 sites99 target enrollmentMay 16, 2022
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- unresectable advanced hepatocellular carcinoma
- Sponsor
- agoya University Graduate School of Medicine
- Enrollment
- 99
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who wish to be excluded from the study. Patients who are pregnant, or lactating, may become pregnant, intend to become pregnant, or who wish to have a baby. Patients with the following serious complications: 1\. Cardiovascular abnormalities such as heart failure, angina pectoris, or arrhythmia are difficult to control even after treatment. 2\. Myocardial infarction within 6 months of onset 3\. Renal failure 4\. Active infectious disease except for viral hepatitis 5\. Active gastrointestinal bleeding 6\. Other active cancer requiring treatment 7\. Hepatic encephalopathy or severe mental disorder 8\. Severe drug allergy 9\. Serious autoimmune disease. Other conditions that the physician deems inappropriate for the safe conduct of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositisjuvenile dermatomyositisrheumatic muscle disease1000381610028302NL-OMON50706niversitair Medisch Centrum Utrecht365
Completed
N/A
A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant TumorsAdvanced Solid MalignanciesJPRN-UMIN000043899ational Cancer Center Hospital East2,768
Recruiting
N/A
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer patients with ESR1 mutations in cellfree DNAbreast cancer, metastasis, ESR1 mutations, chemotherapyNL-OMON25511Erasmus MC Cancer Institute, department of Medical Oncology185
Recruiting
N/A
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cell-free DNA: TAX-ESR1 study.Metastasis of breast cancer10006291NL-OMON46354Erasmus MC, Universitair Medisch Centrum Rotterdam175
Completed
N/A
Multicenter research study on therapeutic efficacy and prognosis of inflammatory bowel diseaseInflammatory bowel diseaseJPRN-UMIN000017856Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University1,850